Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Non-Deal Roadshow (January 2016)
21 slides from Neurizon Therapeutics's roadshow presentation, January 2016
Slide 1: Investor Presentation January 2016
For personal use only ASX: PAA ACN 094 006 023 Investor Presentation January 2016 1
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the Co pa . It does not purport to contain all the For personal use only information that a prospective investor may require in connection with any potential investment in the Company. You s
Slide 3: Corporate Overview
Corporate Overview Proprietary Technology pipeline of clinical-stage oncology drugs – focus on For personal use only drug repurposing - new class of targeted therapy Lead product PPL-1 (Monepantel-MPL) successfully completed Phase I/II – now Phase II ready New Class of Broad Spectrum Targeted An
Slide 4: Financial Snapshot
Financial Snapshot For personal use only ASX Code PAA ACN 094 006 023 Total Shares on Issue 92,503,645 Unlisted Options on Issue 675,000 Market Cap US$7.4M Cash (mrq) US$1.25M Debt (mrq)1 US$500,000 Sales (ttm) US$1.8M (AU$2.6M) Data as of January 11, 2016 1 EFIC loan to Epichem ASX: PAA
Slide 5: Investment Highlights
Investment Highlights Significantly undervalued – substantial investor upside For personal use only MPL proven to be active in Phase I trial Epichem Business enjoying growing revenues – forecast $10M by 2020 Potential for multi-billion dollar assets MPL already approved for veterinary appl
Slide 6: Multiple Key Performance Drivers in 2016
Multiple Key Performance Drivers in 2016 For personal use only MPL-Phase II Success Contract Business Phase III Ready Meeting Sales Targets Capital Growth Phase II with MPL and $10M sales forecasted Accelerate Commercialization by 2021 Partnering Albendazole Support for MPL and Mucin projects pro
Slide 7: MPL is a New Targeted Therapy within the $100B Cancer Treatment Market
MPL is a New Targeted Therapy within the $100B Cancer Treatment Market 1 For personal use only Surgery Stem Cell Radiation Targeted Therapy $100B1 Typically small molecules or monoclonal antibodies Targeted Chemo Therapy MPL Hormonal 1 Reuters ASX: PAA 7
Slide 8: MPL Achieved All Key Phase I Endpoints
MPL Achieved All Key Phase I Endpoints For personal use only 1. Safety – Excellent safety profile as predicted from pre-clinical models 2. Active dose – Identified dosage of MPL from effects on cancer markers in man 3. Efficacy – Determined efficacy by markers and effects on tumours (p70s6K and p4E-
Slide 9: Strong Confidence in Phase II Performance of MPL
Strong Confidence in Phase II Performance of MPL For personal use only Substantial pre-clinical package in cancer models Substantial pre-clinical package as MPL on market with global major (Novartis Animal Health) Activity in naturally occurring canine cancers Activity in a range of human ca
Slide 10: MPL Active in Phase I Trial in Patients Who Fail Other Available Treatments
MPL Active in Phase I Trial in Patients Who Fail Other Available Treatments For personal use only Implications for MPL As a new class of cancer drug with a novel mechanism of action it provides the opportunity to be effective where “ta da d of Ca e has failed Preclinical studies show reversal of
Slide 11: MPL Already Approved for Veterinary Applications
MPL Already Approved for Veterinary Applications For personal use only Novartis Animal Health registered Zolvix (MPL) for the treatment of parasitic diseases in animals Extensive manufacturing and toxicology already established by global major pharma company Over 80 MPL analogues are available
Slide 12: Elevated p70s6k is Associated with Poor Outcomes in Cancer
Elevated p70s6k is Associated with Poor Outcomes in Cancer For personal use only Patients who have a poor response to chemotherapy have high p70s6k levels p70s6k has been implicated to promote malignant transformation of cancers Rapamycin-sensitive p70s6k pathway is a potential novel target fo
Slide 13: High s6k Correlates with Multiple Negative Outcomes
High s6k Correlates with Multiple Negative Outcomes For personal use only Two complexes of mTOR (mammalian target of rapamycin) High s6k (p70s6k) in mTORC1 mTORC2 patients correlates with: PRAS40 Protor mSin1 mTOR mTOR Raptor GβL Rictor GβL Resistance to therapy Deptor Deptor Aggressive disease
Slide 14: Suppression of p70s6k by MPL in Humans
Suppression of p70s6k by MPL in Humans For personal use only D e te r m in a tio n o f p -P 7 0 S 6 K in P B M C o f p a tie n ts tr e a te d w ith M P L D a y 1 b e fo re tre a tm e n t 100 D ay 3 ** * D ay 7 1 ** ** (% c o n tr o l) *** p -P 7 0 S 6 K 50 ****** **** 0 R 01 R 101 R 02 R 102 R 202 R
Slide 15: Suppression of p-4E-BP1 by MPL in Humans
Suppression of p-4E-BP1 by MPL in Humans For personal use only D e te r m in a tio n o f p -4 E -B P 1 in P B M C o f p a tie n ts tr e a te d w ith M P L D a y 1 b e fo re tre a tm e n t 150 D ay 3 D ay 7 1 (% c o n tr o l) p -4 E -B P 1 100 * * * 50 ** ** 0 R 01 R 101 R 02 R 102 R 202 P A0 8 1 Poo
Slide 16: Suppression of p70s6k by MPL in Canines
Suppression of p70s6k by MPL in Canines For personal use only PP-p70s6k - p 7 0 S 6Elisa K E in li sdog a i nPBMC dog PBM C P-p70s6k P - p 7 0 S 6 KElisa E lis ainindog d o g(Mortimer (M o r t im e r Cambell) C a m b e ll) PBMC PBMC Relapse Lymphoma Relapse Lymphoma 125 125 100 100 C o n tro l % 75
Slide 17: mTOR Inhibition May Enhance Antitumor Effects of Other Therapies
mTOR Inhibition May Enhance Antitumor Effects of Other Therapies For personal use only Anti- Estrogens Chemo Radiation mTOR Inhibition GF Anti- Signaling Angiogenics Inhibitors ASX: PAA 17
Slide 18: Synergy Between MPL & Cytotoxic Drugs
Synergy Between MPL & Cytotoxic Drugs1 Provides Potential for Combination Therapy For personal use only 1 Synergy demonstrated on ovarian cancer grown in xenograft-mice ASX: PAA 18
Slide 19: Commercialization of MPL
Commercialization of MPL For personal use only Option on veterinary Joint patent with cancer applications Japanese major Novartis Animal Nihon Health Nohyaku (strong IP position) PharmAust ASX: PAA 19
Slide 20: Experienced Management
Experienced Management For personal use only Dr. Roger Aston, Executive Chairman Previously at Wellcome Research Laboratories, Peptech, Cambridge Antibody Technology, QinetiQ, pSivida, Clinuvel, HalcyGen and Ascent Pharma Health. More recently CEO of Mayne Pharma Group. Robert Bishop, Executive Dire
Slide 21: For personal use only
For personal use only SAM WRIGHT DR ROGER ASTON Director & Company Secretary sam@pharmaust.com Managing Director rogeraston@pharmaust.com ASX: PAA Phone: 61 (0) 408 900 277 Phone: 61 (0) 402 762 204 ACN 094 006 21 023